AU2001267541A1 - Vaccine composition - Google Patents

Vaccine composition

Info

Publication number
AU2001267541A1
AU2001267541A1 AU2001267541A AU6754101A AU2001267541A1 AU 2001267541 A1 AU2001267541 A1 AU 2001267541A1 AU 2001267541 A AU2001267541 A AU 2001267541A AU 6754101 A AU6754101 A AU 6754101A AU 2001267541 A1 AU2001267541 A1 AU 2001267541A1
Authority
AU
Australia
Prior art keywords
vaccine composition
vaccine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001267541A
Inventor
Jean Lang
Jean Francois Saluzzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Publication of AU2001267541A1 publication Critical patent/AU2001267541A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001267541A 2000-05-30 2001-05-29 Vaccine composition Abandoned AU2001267541A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00420112A EP1159969A1 (en) 2000-05-30 2000-05-30 Composition vaccinale
EP00420112 2000-05-30
PCT/EP2001/006871 WO2001091790A1 (en) 2000-05-30 2001-05-29 Vaccine composition

Publications (1)

Publication Number Publication Date
AU2001267541A1 true AU2001267541A1 (en) 2001-12-11

Family

ID=8174059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001267541A Abandoned AU2001267541A1 (en) 2000-05-30 2001-05-29 Vaccine composition

Country Status (7)

Country Link
EP (1) EP1159969A1 (en)
KR (1) KR20030007684A (en)
CN (1) CN1188168C (en)
AU (1) AU2001267541A1 (en)
BR (1) BR0111223A (en)
MX (1) MXPA02011654A (en)
WO (1) WO2001091790A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092592A2 (en) 2002-05-03 2003-11-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
FR2903605A1 (en) 2006-07-12 2008-01-18 Sanofi Pasteur Sa IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE
FR2906724B1 (en) 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
FR2909286B1 (en) 2006-12-01 2012-06-08 Sanofi Pasteur IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE
WO2010141386A1 (en) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
CN108699534B (en) * 2015-11-27 2022-05-24 Km生物医药股份公司 Live virus having attenuated dengue virus library and dengue vaccine comprising the same as antigen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
FR2761698B1 (en) * 1997-04-04 1999-05-07 Pasteur Merieux Serums Vacc TITRATION METHOD OF A COMPLEX VIRAL COMPOSITION

Also Published As

Publication number Publication date
EP1159969A1 (en) 2001-12-05
BR0111223A (en) 2003-04-01
CN1431913A (en) 2003-07-23
CN1188168C (en) 2005-02-09
WO2001091790A1 (en) 2001-12-06
MXPA02011654A (en) 2003-03-27
KR20030007684A (en) 2003-01-23

Similar Documents

Publication Publication Date Title
AP2002002700A0 (en) Vaccine composition
HUP0302117A3 (en) Vaccine composition
AU781269C (en) Pharmaceutical compositions
GB0020089D0 (en) Vaccine Composition
AU2001286233A1 (en) Cement composition
AU2001281887A1 (en) Enamel composition
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AUPQ875700A0 (en) Combination compositions
AU2002214324A1 (en) Medicinal compositions
AU2001290239A1 (en) Medicinal composition
AU2001281965A1 (en) Novel 6-phenylphenanthridines
AU2001241098A1 (en) Composition
AU2001273919A1 (en) Pharmaceutical compositions
AU2001275201A1 (en) Acne-treating composition
AU4085201A (en) Pharmaceutical composition
AU2001267541A1 (en) Vaccine composition
AU2001287852A1 (en) Composition
AU2001235764A1 (en) Compositions
AU2001287732A1 (en) Copolycarbonate-based composition
AU2001262163A1 (en) Composition
AU2001278487A1 (en) Oral composition
AU2001278788A1 (en) Oral composition
AU2001278705A1 (en) Pharmaceutical composition
AU3586401A (en) Pharmaceutical composition